Cargando…
Before Direct-Acting Antivirals for Hepatitis C Virus: Evaluation of Core Protein R70Q and L/C91M Substitutions in Chronically Infected Brazilian Patients Unresponsive to IFN and/or RBV
Although chronic hepatitis C has been effectively treated with direct-acting antivirals (DAAs), the use of conventional therapy with peg-interferon (Peg-IFN) or (predominantly) ribavirin (RBV), remains widespread. R70Q/H and L/C91M amino acid substitutions in the hepatitis C virus (HCV) core protein...
Autores principales: | Campos, Letícia Bomfim, de Almeida, Nathália Alves Araújo, de Santana, Catarina Góis, Barbosa, Evorah Nascimento Pereira, Horta, Marco Aurelio Pereira, Amendola Pires, Márcia, Brandão Mello, Carlos Eduardo, de Paula, Vanessa Salete, de Barros, José Júnior França |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9863677/ https://www.ncbi.nlm.nih.gov/pubmed/36680226 http://dx.doi.org/10.3390/v15010187 |
Ejemplares similares
-
Cytokine profile during occult hepatitis B virus infection in chronic hepatitis C patients
por: Ribeiro, Camilla Rodrigues de Almeida, et al.
Publicado: (2021) -
Pretreatment Predictors of Response to PegIFN-RBV Therapy in Egyptian Patients with HCV Genotype 4
por: Rizk, Hanan H., et al.
Publicado: (2016) -
A Model-Based Illustrative Exploratory Approach to Optimize the Dosing of Peg-IFN/RBV in Cirrhotic Hepatitis C Patients Treated With Triple Therapy
por: Laouénan, C, et al.
Publicado: (2015) -
Changes in immune activation in the T Cell compartments of HIV HCV coinfected patients during PEG IFN RBV treatment
por: Menard, Amélie, et al.
Publicado: (2012) -
Identification of mutations in the HVR1 and PKR-BD regions in HCV-infected patients resistant to PEG-IFNα/RBV therapy
por: Holysz, M., et al.
Publicado: (2015)